Catalent COVID-19 Response
From the start of the pandemic, Catalent was able to put our advanced capabilities to work. We immediately leveraged our major, global investments in biologics production capacity, and accelerated our growth plans, to fight the pandemic and provide a variety of solutions. These investments included expansion of drug substance and drug product sterile scale-up and manufacturing for vaccines and treatments, as well as growth to support clinical development, cold-storage supply chain distribution of critical materials, and analytical testing.
By the end of 2021, Catalent had produced over a billion COVID-19 vaccines and treatments, while simultaneously keeping plants operational and manufacturing all regular life-saving and life enhancing products for customers around the world.
Throughout the pandemic, we have significantly expanded our labor force to meet the needs of patients and customers, hiring and training thousands of new employees across facilities in the U.S. and Europe to help meet the increased global demand for COVID-19-related products, among other things, and manage supply worldwide for clinical trials. Throughout this workforce expansion, our commitment to the engagement, growth, and development of our people has remained steadfast.
At an unprecedented pace, Catalent executed on pre-existing strategic growth plans to accelerate the availability of vaccines and other COVID-19-related response products. In the first several months of the pandemic, we were awarded work on more than 100 COVID-19-related products by over 60 customers, including antivirals, vaccines, diagnostics, and treatments spanning biologics, gene therapy, oral technologies, softgels and clinical supply. Importantly, we have supported the critical production of the Moderna, Johnson & Johnson, and AstraZeneca COVID-19 vaccines. Our expertise, strategic investments, and implementation of advanced technologies will enable us to continue producing greater supplies of vaccines and treatments looking forward.
Catalent’s ability to produce COVID-19 vaccines and therapeutics was critically supported by our investments in assets focused on biologics manufacture at scale. In the last few years, we have:
- increased the number of manufacturing trains for drug substance production in single-use bioreactors at our Madison, Wisconsin, facility;
- purchased, installed, and validated multiple new lines for the sterile fill and finish of biologic drug product at our Bloomington, Indiana, site;
- substantially increased the number of manufacturing suites at our viral vector and RNA production facility in Harmans, Maryland; and
- purchased, installed, and validated a new sterile fill and finish line at our Anagni, Italy, facility, which is particularly important to capacity in Europe.
Catalent has always been a leader in helping innovators scale up and reliably produce millions of doses of treatments using the latest drug delivery technologies. We are proud of our ongoing efforts during the COVID-19 pandemic and excited about further expanding and advancing our capabilities to serve current and future customers.
Critically, since the onset of the pandemic, Catalent has worked closely with industry and government partners across the world to scale up operations and deliver solutions with unprecedented speed. We were incredibly proud to support the U.S. administration’s effort to build a vaccine capability to address the pandemic (originally known as “Operation Warp Speed”), reflecting the prominence of Catalent’s capabilities on a national scale. We are also proud to have manufactured a substantial number of doses for our clients’ programs to supply countries outside the U.S., U.K., and E.U. with vaccines, and look forward to our continuing work with key stakeholders to alleviate the worldwide impact of the pandemic and bolster much needed capabilities and capacity.